Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Kesimpta is a prescription CD20-directed cytolytic antibody containing ofatumumab. It is indicated for relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Each prefilled pen or syringe contains 20 mg in 0.4 mL.
read more about kesimpta ...Ofatumumab binds to CD20 on pre-B and mature B lymphocytes. Binding leads to antibody-dependent cellular cytolysis and complement-mediated lysis of B cells. The exact mechanism responsible for its therapeutic effects in multiple sclerosis is not established.
Kesimpta is used in adults with relapsing forms of multiple sclerosis. Hepatitis B screening, quantitative immunoglobulins, and liver tests are obtained before treatment. Active hepatitis B infection is a contraindication.
The initial regimen is 20 mg by subcutaneous injection at weeks 0, 1, and 2. Monthly 20 mg dosing starts at week 4. The first injection is performed under guidance from a healthcare professional, and later doses are intended for patient self-administration after proper training.
Serious concerns include severe infections, hepatitis B reactivation, progressive multifocal leukoencephalopathy risk, injection-related reactions, anaphylaxis, reduced immunoglobulin levels, and liver injury. Live vaccines are avoided during treatment and until B-cell recovery after discontinuation.
Kesimpta treats relapsing forms of multiple sclerosis in adults.
The initial regimen is 20 mg at weeks 0, 1, and 2.
Monthly 20 mg injections begin at week 4.
Yes. Later doses are intended for self-administration after the first injection is performed under healthcare professional guidance and the patient receives proper training.
Five-Year Safety and Efficacy Outcomes With Ofatumumab in Patients With Relapsing Multiple Sclerosis. https://pubmed.ncbi.nlm.nih.gov/40652442/. Date Accessed October 7, 2026.
KESIMPTA (Ofatumumab) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a8a3f53-2062-48ff-9dbe-b939df133ca3. Date Accessed October 7, 2026.
Ofatumumab Injection (Multiple Sclerosis): MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a621050.html. Date Accessed October 7, 2026.
Ofatumumab Versus Teriflunomide in Multiple Sclerosis. https://pubmed.ncbi.nlm.nih.gov/32757523/. Date Accessed October 7, 2026.
Six-Year Safety and Efficacy Outcomes With First-Line Ofatumumab in Recently Diagnosed Treatment-Naive Patients With Relapsing Multiple Sclerosis. https://pubmed.ncbi.nlm.nih.gov/41380509/. Date Accessed October 7, 2026.